Eli Lilly’s Q2 Earnings Surpass Expectations, Raises Full-Year Outlook
Eli Lilly reported stellar second-quarter earnings, significantly exceeding market expectations, driven by robust sales of its diabetes drug Mounjaro and weight loss injection Zepbound. The pharmaceutical...